High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications
- PMID: 23921492
- DOI: 10.1007/s00467-013-2575-8
High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications
Abstract
Background: Coronary calcifications (CC) portend increased mortality in adults receiving hemodialysis (HD), however the risk factors associated with CC progression are not well known in pediatric patients. Our previous cross-sectional studies demonstrated high CC prevalence (31 %) in pediatric patients, which were significantly associated with high serum phosphorus (P), fibroblast growth factor 23 (FGF) levels, dialysis vintage, and low cholesterol. The current study was undertaken to determine and elucidate CC progression in pediatric HD patients.
Methods: A 1-year prospective longitudinal study of 16 pediatric patients (ten male; mean age, 16.9 ± 3 years; range, 10.1-20.4 years) receiving chronic HD was conducted.
Results: CC were observed in five of 16 (31.3 %) patients on baseline computed tomogram (CT) scan; 14/16 patients underwent 1-year CT. All patients with initial CC who completed CT at 1 year (3/5) progressed; one patient had new CC and none of the patients had resolved CC. Mean Agatston score increased from 23.4 ± 18.06 HU (baseline) to 169 ± 298.9 HU. Patients with CC progression had higher mean serum P (8.6 ± 1.8 mg/dl vs. 6.3 ± 1.1 mg/dl, p = 0.015) and FGF 23 levels (3,994 ± 860.5 pg/ml vs. 2,327 ± 1,206.4 pg/ml, p = 0.028). Serum P and FGF 23 levels were positively correlated with final Agatston scores (R = 0.65, p = 0.01 for serum P and R = 0.54, p = 0.045 for FGF 23) and change in Agatston scores (R = 0.65, p = 0.01 for serum P and R = 0.52, p = 0.048 for FGF 23).
Conclusions: Our study shows that CC is progressive in pediatric patients receiving HD and that increased serum P and FGF 23 levels are associated with this progression.
Similar articles
-
Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients.Pediatr Nephrol. 2011 Jun;26(6):945-51. doi: 10.1007/s00467-011-1822-0. Epub 2011 Feb 27. Pediatr Nephrol. 2011. PMID: 21359960
-
Cardiac calcifications are more prevalent in children receiving hemodialysis than peritoneal dialysis.Clin Nephrol. 2014 Apr;81(4):231-7. doi: 10.5414/cn108178. Clin Nephrol. 2014. PMID: 24656313
-
FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients.BMC Nephrol. 2013 Nov 1;14:241. doi: 10.1186/1471-2369-14-241. BMC Nephrol. 2013. PMID: 24180481 Free PMC article. Clinical Trial.
-
Malnutrition-inflammation-coronary calcification in pediatric patients receiving chronic hemodialysis.Hemodial Int. 2010 Jul;14(3):263-9. doi: 10.1111/j.1542-4758.2010.00442.x. Epub 2009 Nov 17. Hemodial Int. 2010. PMID: 20491972
-
Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23.J Nephrol. 2011 May-Jun;24(3):313-21. doi: 10.5301/JN.2010.5818. J Nephrol. 2011. PMID: 20954136
Cited by
-
Iron Sucrose: A Double-Edged Sword in High Phosphate Media-Induced Vascular Calcification.Calcif Tissue Int. 2021 Jun;108(6):798-807. doi: 10.1007/s00223-020-00804-1. Epub 2021 Jan 13. Calcif Tissue Int. 2021. PMID: 33439323
-
Role of klotho and fibroblast growth factor 23 in arterial calcification, thickness, and stiffness: a meta-analysis of observational studies.Sci Rep. 2024 Mar 8;14(1):5712. doi: 10.1038/s41598-024-56377-8. Sci Rep. 2024. PMID: 38459119 Free PMC article.
-
FGF-23 as a Biomarker for Carotid Plaque Vulnerability: A Systematic Review.Med Sci (Basel). 2025 Mar 10;13(1):27. doi: 10.3390/medsci13010027. Med Sci (Basel). 2025. PMID: 40137447 Free PMC article.
-
FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.Am J Physiol Endocrinol Metab. 2014 Sep 1;307(5):E426-36. doi: 10.1152/ajpendo.00264.2014. Epub 2014 Jul 22. Am J Physiol Endocrinol Metab. 2014. PMID: 25053401 Free PMC article.
-
Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.Nat Rev Nephrol. 2014 May;10(5):268-78. doi: 10.1038/nrneph.2014.49. Epub 2014 Apr 1. Nat Rev Nephrol. 2014. PMID: 24686452 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical